CCIA
BBIO icon

Campbell & Co Investment Adviser’s BridgeBio Pharma BBIO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Buy
+35,378
New +$2.48M 0.14% 236
2025
Q3 		– Sell
-35,053
Closed -$1.51M – 1088
2025
Q2 		$1.51M Buy
+35,053
New +$1.27M 0.1% 335
2024
Q1 		– Sell
-23,071
Closed -$931K – 1106
2023
Q4 		$931K Buy
23,071
+7,775
+51% +$234K 0.08% 418
2023
Q3 		$403K Buy
+15,296
New +$434K 0.05% 608

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Campbell & Co Investment Adviser's BBIO Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 35,378 shares worth $2.63M. The stake represents 0.14% of the portfolio and ranks #236 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in BBIO as recently as Q2 2025.

Campbell & Co Investment Adviser first reported a position in BBIO in Q3 2023 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Campbell & Co Investment Adviser held 35,378 shares of BridgeBio Pharma worth $2.63M as of Q2 2026.
  • BridgeBio Pharma was a new Campbell & Co Investment Adviser position in Q2 2026.
  • BridgeBio Pharma made up 0.14% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #236 holding.
  • Campbell & Co Investment Adviser first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 4 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.